title: [Fertility and testicular function in a patient with germ cell extragonadal tumor. A report of a case].
abstract: Males are affected from primary extragonadal germ cell tumors with a frequency of 2 to 5%. There is a high incidence of infertility of more than 60% and most of the cases have azoospermia due to testicular damage. The hormonal profile of these patients shows normal luteinizing hormone, normal follicle stimulating hormone and normal testosterone and estradiol. We communicate the case of a male who had a primary retroperitoneal germ cell tumor with a low title of chorionic gonadotropin, elevated estradiol and normal testosterone, prolactin and seminogram. Before beginning treatment with chemotherapy, his wife became pregnant delivering twins, both males. The patient was treated with chemo and radiotherapy after which he became azoospermic with an increase in both luteinizing hormone and follicle stimulating, decreased levels of estradiol and without alteration in prolactin and testosterone. The pituitary testicle axis was affected by the tumor, but the microenvironment of the testicles did not seem to be damaged only after initiating treatment.
authors.affiliation: Laboratorio de Biología de la Reproducción, Hospital Juárez de México, Secretaría de Salud, colonia Magdalena de las Salinas, DF México. capi@todito.com
authors.forename: José Maria
authors.initials: JM
authors.lastname: Tovar Rodríguez
authors.forename: Leticia
authors.initials: L
authors.lastname: Bañuelos Avila
authors.forename: Irma
authors.initials: I
authors.lastname: Chávez Zúñiga
authors.forename: Francisco
authors.initials: F
authors.lastname: García Rodríguez
authors.forename: Víctor Manuel
authors.initials: VM
authors.lastname: Vargas Hernández
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D053713:Azoospermia / Q000097:blood / Q000209:etiology; D006063:Chorionic Gonadotropin / Q000097:blood; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005298:Fertility; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D007231:Infant, Newborn; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011247:Pregnancy; D011272:Pregnancy, Multiple; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D018239:Seminoma / Q000188:drug therapy / Q000503:physiopathology* / Q000532:radiotherapy; D013737:Testis / Q000503:physiopathology*; D013739:Testosterone / Q000097:blood; D014427:Twins
chemical_list: D006063:Chorionic Gonadotropin; D013739:Testosterone; D003520:Cyclophosphamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002945:Cisplatin